Effects on classic cardiovascular risk factors CVOTs on GLP-1RAs Data from the major CVOTs ELIXA, SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6, LEADER, REWIND, and AMPLITUDE-O [53, 54, 56, 59,60,61,62,63] support the overall safety of GLP-1RAs relative to major cardiovascular outcomes
Stanley Althof, these results suggested PT-141 meaningfully improved the psychosocial aspects of sexual function, not just the physical ability to get an erection.In other words, men felt more assured and satisfied in their sexual encounters when using PT-141
This innovative approach positions orforglipron as a promising addition to the latest incretin medicines for diabetes and obesity management
For patients using GLP-1 agonists primarily for weight management rather than diabetes control, temporary adjustment typically poses less immediate concern regarding blood glucose levels